Skip to content

Economic and Clinical Benefit of Remote Monitoring Among Defibrillator Patients by Indication Subgroups (BENEFIT-RM)

Economic and Clinical Benefit of Remote Monitoring Among Defibrillator Patients by Indication Subgroups (BENEFIT-RM)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05106062
Enrollment
1140
Registered
2021-11-03
Start date
2020-12-21
Completion date
2029-09-30
Last updated
2024-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With Defibrillator

Keywords

defibrillator, remote monitoring, benefit, economic, clinical

Brief summary

Remote monitoring is now universally available for all cardiac implantable electronic devices (CIEDs), and it has become the standard of care for the management of patients with these devices. In many countries, it is being proven that patients with implantable defibrillator (ICD) or cardiac resynchronizing therapy (CRT) can benefit from remote monitoring (RM) both economically and clinically. From previous RM related clinical studies, it is reasonably accepted that hospitalization cost and mortality rate is comparably higher in defibrillator patients compared to pacemaker indicated patients. However, it is yet to be discovered which group of defibrillator patients are the most beneficiaries using remote monitoring system. In this study, the investigators would further categorize defibrillator patients into different indication subgroups and compare both economic and clinical benefits among different indication. By comparing economic and clinical benefits of remote monitoring by different subgroups, the investigators might be able to set a guideline on which group of patients should be strongly suggested for remote monitoring utilization. Therefore, the investigators perform a prospective study in Korean population to compare economic and clinical benefits of RM compared to conventional follow-up in overall study cohort and by different subgroups. (ICD & CRT-D).

Detailed description

The investigators propose to prospectively recruit 556 patients with ICD or CRT-D implantation in 10 sites in Korea. * Eligible patients should be enrolled in remote monitoring system 0 to 45 days after successful device implantation and then randomly assigned in a 1:1 ratio to the RM or conventional follow-up group. * In the RM follow-up arm, the patients are not mandated to visit the clinic unless there is unscheduled call due to adverse event notification. * In the conventional follow-up arm, the patients should be seen at the clinic according to each center's custom but no longer than 1 year between each visit. Follow-up should be continued accordingly until two-years of device implant.

Interventions

DEVICEon remote monitoring

This group will turn on the RM function 0 to 45 days after defibrillator implantation. Patient should be seen at clinic once a year, or if there is any adverse event notification

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. All ICD and CRT-D patients who are over the age of 18 2. Ability to provide informed consent and to complete the study and required follow-up

Exclusion criteria

1. Those who refuse to participate in the trial. 2. Those who refuse to use remote monitoring system or who live in an environment where remote monitoring system cannot be utilized. 3. Patient who refuse to use or expected to use less than 75% of remote monitoring system.

Design outcomes

Primary

MeasureTime frameDescription
Major adverse eventup to 2 yearsDefinition of major adverse events (MAE) 1. fatal or life-threatening 2. prompted or prolonged a hospitalization; 3. caused major or permanent disability or injury; 4. required an intervention to prevent permanent disability or injury
Major adverse event, including death from any cause, cardiovascular, and procedure- or device-related MAE.up to 2 yearsDefinition of device-related adverse events 1. delivery of ≥1 inappropriate shock(s); 2. delivery of ≥2 symptomatic inappropriate ATP; 3. symptomatic defibrillator-mediated tachycardia; 4. infection or extrusion of the ICD; 5. ineffective pacing; 6. intermittent or permanent undersensing; 7. clinical phrenic stimulation; and 8. lead or pulse generator dysfunction.

Secondary

MeasureTime frameDescription
Economic benefit by remote monitoringup to 2 years\- Cost Incurred by the patient towards the transportation
Economic benefit by remotemonitoringup to 2 years\- Cost towards loss of employment for time spent in hospital for check-up of patient

Countries

South Korea

Contacts

Primary ContactTaehoon Kim
thkimcardio@yuhs.ac+82 02-2228-8460

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026